Clinical review of the impacts of hepatitis C

15. References

1. Practitioner Services Division of National Services Scotland of the NHS Data on SIBSS beneficiaries (Knowles D, Richards S, personal commendation).

2. UK Department of Health and Social Care. Review of the support available to individuals infected with hepatitis C and/or HIV by NHS supplied blood transfusion or blood products, and their dependants. 2011. https://www.gov.uk/government/publications/review-of-the-support-available-to-individuals-infected-with-hepatitis-c-and-or-hiv-by-nhs-supplied-blood-transfusions-or-blood-products-and-their-dependants

3. Financial Review Group Final Report. Contaminated Blood: Financial Support: Conclusions and Recommendations. 2015. https://haemophiliascotland.files.wordpress.com/2015/11/contaminated-blood-financial-support-conclusions-and-recommendations.pdf

4. Liang T and Ghany M. Therapy of Hepatitis C – Back to the future. The New England Journal of Medicine 2014; 370: 2043-2047.

5. Health Protection Scotland and Glasgow Caledonian University: Blood borne viruses and sexually transmitted infections: Scotland 2017. Glasgow: Health Protection Scotland December 2017. www.hps.scot.nhs.uk

6. Scotland’s Sexual Health and Blood Borne Virus (Framework) Data Portal www.hps.scot.nhs.uk/bbvsti/shbbvframeworkdataportal.aspx

7. The Penrose Inquiry Recommendation. Report of a Scottish Government Short-Life Working Group. September 2016 http://www.gov.scot/Resource/0050/00505099.pdf

8. Hutchinson SJ, Bird SM, Goldberg DJ. Modelling the Current and Future Disease Burden of Hepatitis C among Injection Drug Users in Scotland. Hepatology 2005; 42: 711-723.

9. Van de Meer A, Feld J, Hofer H et al. Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication. Journal of Hepatology 2017; 66:485-493.

10. Innes H, Barclay ST, Hayes PC, Fraser A, Dillon JF, Stanley A, Bathgate A, McDonald SA, Goldberg D, Valerio H, Fox R, Kennedy N, Bramley P, Hutchinson SJ. The risk of hepatocellular carcinoma in cirrhotic patients with hepatitis C and sustained viral response: role of the treatment regimen. Journal of Hepatology. 2017, Nov 16. pii: S0168-8278(17)32429-7.

11. Scottish Government. Hepatitis C Action Plan for Scotland: Phase II (May 2008-March 2011). Scottish Government; 2008. http://www.gov.scot/Resource/Doc/222750/0059978.pdf

12. The Scottish Government Hepatitis C Treatment and Therapies Group Report (Revised February 2017) www.gov.scot/topics/health/services/sexual-health/hepc-treatmentreport2017

13. Goldberg D, Hutchinson S, Innes H, Erikson A, Brown G, Dillon J. Scotland’s Hepatitis C Action Plan: the Odyssey Continues towards Elimination. Epidemiology, Prevention, Management and Elimination of Hepatitis C: Volume III Elimination. Springer Nature Publications (in press)

14. Hutchinson S, Valerio H, Dillon J, Fox R, Yeung, Innes H, et al. Reduction in the incidence of hepatitis C-related decompensated cirrhosis associated with national scale-up of direct-acting antiviral ( DAA) therapies targeting patients with advanced liver fibrosis. International Liver Congress, Paris, 24 ^th Nov 2017.

15. Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic Manifestations of Hepatitis C: A Meta-analysis of Prevalence, Quality of Life, and Economic Burden. Gastroenterology 2016; 150: 1599-1608.

16. Dowsett L, Coward S, Lorenzetti D, MacKean G, Clement F. Living with Hepatitis C Virus: A Systematic Review and Narrative Synthesis of Qualitative Literature. Canadian Journal of Gastroenterology and Hepatology Volume 2017, Article ID 3268650; 11 pages.

17. Ruso M, Fried M. Side Effects of Therapy for Chronic Hepatitis C. Gastroenterology 2003; 124:1711-1719.

18. Dusheiko G. Side Effects of Alpha Interferon in Chronic Hepatitis C. Hepatology 1997; 26(Suppl 1): 112S-121S.

19. Younossi Z, Stepanova M, Asselah T, Foster G, Pater K, Bräu N, et al. Hepatitis C in Patients With Minimal or No Hepatic Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes. Clinical Infectious Diseases 2017; XX(00):1-9.

20. Scottish Infected Blood Forum. Hepatitis C Virus ( HCV). Contaminated Blood Scoping Exercise in Respect of People Infected with Hepatitis C as a Result of NHS Contaminated Blood Transfusions and Blood Products in Scotland. March 2015.

21. Harris H, Ramsay M, Andrews N. Survival of a national cohort of hepatitis C virus infected patients, 16 years after exposure. Epidemiol. Infect. (2005).000, 1-6.

22. Seef L, Bushell-Bales Z, Wright E et al. Long Term Mortality after Transfusion Associated Non-A, Non-B Hepatitis. NEJM 1992;327:1906-11.

23. Kielland K, Skaugk, Amundsen E, Dalgard O et al. All-cause and liver-related mortality in hepatitis C infected drug users followed for 33 years: A controlled study. Journal of Hepatology 2013;58:31-37

24. Backus L, Belperio P, Shahoumian T, Mole L. Direct-Acting Antiviral Sustained Virologic Response: Impact on Mortality in Patients without Advanced Liver Disease. Hepatology.

25. Innes HA, McDonald SA, Dillon JF, Allen S, Hayes PC, Goldberg D, et al. Towards a more complete understanding of the association between a hepatitis C sustained viral response and cause-specific outcomes. Hepatology. August 2015; 62(2):355-64

26. UK Department of Health. Infected Blood: Government Response to consultation on special category mechanism and other support in England. 2017. https://www.gov.uk/government/consultations/infected-blood-support-special-category-mechanism